VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative preclinical data while reducing the number of animals required for drug development. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays, computational modeling and three-dimensional spheroid models, according to an October 7, 2026, company announcement.
The move matters because preclinical studies that rely on traditional animal models often fail to predict human responses, leading to high failure rates in clinical trials. By adopting NAMs, which are aligned with FDA guidance, VERAXA aims to improve the translational relevance of its experimental findings. This is particularly critical for its pipeline of BiTAC T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates, which are designed to treat cancer by harnessing the immune system.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This suggests that the NAMs approach can yield robust efficacy signals with far fewer animals, potentially accelerating timelines and reducing costs.
The implications extend beyond animal welfare. For investors, the strategy could enhance the probability of success for VERAXA’s candidates as they move toward clinical trials. Human-relevant data may also strengthen regulatory submissions and support faster review processes. As the FDA and other agencies increasingly encourage NAMs, companies that adopt these methods early may gain a competitive advantage. VERAXA’s focus on BiTAC-based therapies, which are complex biologics, makes the need for predictive models especially acute. The reduction in animal use also addresses ethical concerns and may align with environmental, social and governance (ESG) criteria that some investors prioritize.
For a deeper look at VERAXA’s pipeline and strategy, see the full announcement. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. MissionIR, a specialized communications platform, distributes syndicated content to enhance visibility for private and public companies. It is part of the Dynamic Brand Portfolio at IBN, which offers wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. For more information, visit MissionIR. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
